FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2045861350> ?p ?o ?g. }

• W2045861350 endingPage "397" @default.
• W2045861350 startingPage "389" @default.
• W2045861350 abstract "The N-methyl-D-aspartate (NMDA) receptor is a ligand-gated ion channel which is widely distributed in the central nervous system (CNS), and which mediates most of the fast excitatory neuronal transmission in the CNS. As with other ligand-gated ion channels, the NMDA receptor is a macromolecular complex which possesses a number of intricate regulatory sites within and around a central ion channel. The key regulatory components for which prototypic antagonists have been developed are the competitive NMDA antagonist binding site, the non-competitive NMDA antagonist binding site within the ion channel, and the NMDA receptor-associated glycine antagonist site. The binding domains for each of these binding sites possess discrete and non-overlapping SAR with regard to the chemical series developed to date. The potential utility of NMDA antagonists in the treatment of stroke and traumatic brain injury was investigated soon after the synthesis of the first bioavailable NMDA antagonists. Efficacy in preclinical models was demonstrated with both competitive and non-competitive NMDA antagonists. However, preclinical testing also revealed potentially clinically-limiting side-effects which included phencyclidine (PCP)-like actions indicative of possible psychotomimetic activity, cerebral vacuolisat<$M[wood_2]>ion of limbic cortical neurones, low therapeutic indices relative to incapacitating motor side-effects and, in the case of non-competitive antagonists, hypertension. These limitations have led to the design of clinical trials that should define the therapeutic index for this type of compound in humans. Currently, the first competitive antagonist to enter clinical trials, selfotel, is on hold, while D-CPPene is still in development. The non-competitive antagonist, aptiganel, is currently in Phase III clinical trials and its therapeutic efficacy and index should be defined in 1997 and 1998. The well-defined limitations of competitive and non-competitive NMDA antagonists have been a key impetus in the investigation of alternative approaches to modulating the NMDA receptor complex. In the case of glycine site antagonists, these compounds have been shown in preclinical studies to be devoid of PCP-like actions and the neuronal vacuolisation associated with the competitive and non-competitive NMDA antagonists. This has induced the development of a number of chemical series with at least three compounds currently in Phase I and II clinical trials. These include ACEA 1021, GV150526A and ZD9379. Clinical efficacies and therapeutic indices of these compounds should be defined in 1998 and 1999. An alternative approach using a partial agonist of the glycine site (1-aminocyclopropane-carboxylic acid, ACPC) has been halted in Phase I. Another approach which has led to the development of NMDA receptor antagonists, selective for the NMDA receptor subunits 1A/2B (NR1A/2B subtype), was the discovery in early studies of the neuroprotective actions of ifenprodil. Structural analogues include eliprodil, CP-101,606 and lubeluzole. In the cases of eliprodil and lubeluzole, these compounds have demonstrated neuroprotection in preclinical models, but they possess the extremely dangerous side-effect of increasing cardiac repolarisation time (i.e., increased QTc interval). The therapeutic index for these compounds is low. This has led to the termination of eliprodil's development and has limited the current dosing strategy with lubeluzole. It has not been disclosed if CP-101,606 possesses this dose-limiting side-effect. In summary, strategies for drug design and development based on our knowledge of the NMDA receptor complex have led to the development of a new generation of compounds for the treatment of stroke and traumatic brain injury, which remain to be evaluated in the clinic. The success of this approach will be defined in the next two to three years." @default.
• W2045861350 created "2016-06-24" @default.
• W2045861350 creator A5021691550 @default.
• W2045861350 creator A5049644101 @default.
• W2045861350 date "1997-04-01" @default.
• W2045861350 modified "2023-09-27" @default.
• W2045861350 title "N-methyl-D-aspartate antagonists for stroke and head trauma" @default.
• W2045861350 cites W141553956 @default.
• W2045861350 cites W1608350875 @default.
• W2045861350 cites W1969159265 @default.
• W2045861350 cites W1969217550 @default.
• W2045861350 cites W1972116436 @default.
• W2045861350 cites W1972777307 @default.
• W2045861350 cites W1973217963 @default.
• W2045861350 cites W1973307241 @default.
• W2045861350 cites W1976772152 @default.
• W2045861350 cites W1976909443 @default.
• W2045861350 cites W1995056605 @default.
• W2045861350 cites W1995814885 @default.
• W2045861350 cites W2000922813 @default.
• W2045861350 cites W2001198148 @default.
• W2045861350 cites W2004187689 @default.
• W2045861350 cites W2009798253 @default.
• W2045861350 cites W2010937750 @default.
• W2045861350 cites W2012555960 @default.
• W2045861350 cites W2013303904 @default.
• W2045861350 cites W2013398602 @default.
• W2045861350 cites W2015607927 @default.
• W2045861350 cites W2020438397 @default.
• W2045861350 cites W2022777522 @default.
• W2045861350 cites W2022867077 @default.
• W2045861350 cites W2023152311 @default.
• W2045861350 cites W2024173492 @default.
• W2045861350 cites W2024879016 @default.
• W2045861350 cites W2028318221 @default.
• W2045861350 cites W2029524413 @default.
• W2045861350 cites W2030463961 @default.
• W2045861350 cites W2032216760 @default.
• W2045861350 cites W2038704879 @default.
• W2045861350 cites W2047049678 @default.
• W2045861350 cites W2049114716 @default.
• W2045861350 cites W2056826168 @default.
• W2045861350 cites W2072235811 @default.
• W2045861350 cites W2080804029 @default.
• W2045861350 cites W2080980389 @default.
• W2045861350 cites W2087753104 @default.
• W2045861350 cites W2094313850 @default.
• W2045861350 cites W2094906883 @default.
• W2045861350 cites W2101738963 @default.
• W2045861350 cites W2102038131 @default.
• W2045861350 cites W2114007783 @default.
• W2045861350 cites W2128304152 @default.
• W2045861350 cites W2143773297 @default.
• W2045861350 cites W2146131556 @default.
• W2045861350 cites W2170029299 @default.
• W2045861350 cites W2949574343 @default.
• W2045861350 cites W51778931 @default.
• W2045861350 cites W86709468 @default.
• W2045861350 doi "https://doi.org/10.1517/13543784.6.4.389" @default.
• W2045861350 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15989606" @default.
• W2045861350 hasPublicationYear "1997" @default.
• W2045861350 type Work @default.
• W2045861350 sameAs 2045861350 @default.
• W2045861350 citedByCount "25" @default.
• W2045861350 countsByYear W20458613502012 @default.
• W2045861350 countsByYear W20458613502013 @default.
• W2045861350 countsByYear W20458613502014 @default.
• W2045861350 countsByYear W20458613502017 @default.
• W2045861350 countsByYear W20458613502018 @default.
• W2045861350 countsByYear W20458613502022 @default.
• W2045861350 countsByYear W20458613502023 @default.
• W2045861350 crossrefType "journal-article" @default.
• W2045861350 hasAuthorship W2045861350A5021691550 @default.
• W2045861350 hasAuthorship W2045861350A5049644101 @default.
• W2045861350 hasConcept C112592302 @default.
• W2045861350 hasConcept C126322002 @default.
• W2045861350 hasConcept C169760540 @default.
• W2045861350 hasConcept C170493617 @default.
• W2045861350 hasConcept C17077164 @default.
• W2045861350 hasConcept C185592680 @default.
• W2045861350 hasConcept C2776885963 @default.
• W2045861350 hasConcept C2778851735 @default.
• W2045861350 hasConcept C2781065190 @default.
• W2045861350 hasConcept C50254741 @default.
• W2045861350 hasConcept C67018056 @default.
• W2045861350 hasConcept C71924100 @default.
• W2045861350 hasConcept C82617044 @default.
• W2045861350 hasConcept C86803240 @default.
• W2045861350 hasConcept C86811712 @default.
• W2045861350 hasConcept C98274493 @default.
• W2045861350 hasConceptScore W2045861350C112592302 @default.
• W2045861350 hasConceptScore W2045861350C126322002 @default.
• W2045861350 hasConceptScore W2045861350C169760540 @default.
• W2045861350 hasConceptScore W2045861350C170493617 @default.
• W2045861350 hasConceptScore W2045861350C17077164 @default.
• W2045861350 hasConceptScore W2045861350C185592680 @default.
• W2045861350 hasConceptScore W2045861350C2776885963 @default.
• W2045861350 hasConceptScore W2045861350C2778851735 @default.

• next